MA40538A - Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci - Google Patents
Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ciInfo
- Publication number
- MA40538A MA40538A MA040538A MA40538A MA40538A MA 40538 A MA40538 A MA 40538A MA 040538 A MA040538 A MA 040538A MA 40538 A MA40538 A MA 40538A MA 40538 A MA40538 A MA 40538A
- Authority
- MA
- Morocco
- Prior art keywords
- epoxide hydrolase
- soluble epoxide
- hydrolase inhibitors
- inhibitors
- soluble
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043275P | 2014-08-28 | 2014-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40538A true MA40538A (fr) | 2021-04-07 |
Family
ID=55400481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040538A MA40538A (fr) | 2014-08-28 | 2015-08-26 | Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10081616B2 (fr) |
| EP (1) | EP3186228A4 (fr) |
| JP (1) | JP2017525777A (fr) |
| CN (2) | CN111454246A (fr) |
| AU (2) | AU2015306643B2 (fr) |
| CA (1) | CA2958881A1 (fr) |
| MA (1) | MA40538A (fr) |
| WO (1) | WO2016033150A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081616B2 (en) * | 2014-08-28 | 2018-09-25 | X-Chem, Inc. | Soluble epoxide hydrolase inhibitors and uses thereof |
| US11382894B2 (en) | 2017-03-30 | 2022-07-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Pharmaceutical compositions for use in the treatment of cardiovascular calcification |
| WO2021127517A1 (fr) * | 2019-12-18 | 2021-06-24 | Intra-Cellular Therapies, Inc. | Nouvelles utilisations |
| WO2024105225A1 (fr) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3245950A1 (de) * | 1981-12-24 | 1983-07-07 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur herstellung substituierter pyridine |
| AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
| US20040067985A1 (en) * | 2002-10-04 | 2004-04-08 | Fortuna Haviv | Method of inhibiting angiogenesis |
| JP2009528992A (ja) * | 2006-02-16 | 2009-08-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素阻害剤として有益な置換ピリジンアミン化合物 |
| US20090111791A1 (en) * | 2006-03-10 | 2009-04-30 | Boehringer Ingelheim International Gmbh | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same |
| CN101522614B (zh) * | 2006-08-09 | 2014-06-25 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的化合物 |
| CA2672373C (fr) * | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Derives de la nicotinamide en tant qu'inhibiteurs de h-pgds et leur utilisation dans le traitement de maladies liees aux prostaglandines d2 |
| EP2002834A1 (fr) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryle/hétarylamides en tant que modulateurs du récepteur EP2 |
| WO2009151800A1 (fr) * | 2008-05-07 | 2009-12-17 | Merck & Co., Inc. | Inhibiteurs d’époxyde hydrolase solubles, compositions contenant de tels composés et procédés de traitement |
| JP2011524893A (ja) * | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
| JP2011524894A (ja) * | 2008-06-18 | 2011-09-08 | ファイザー・リミテッド | ニコチンアミド誘導体 |
| EP2149551A1 (fr) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | Dérivés de N-(indol-3-ylalkyl)-(hétéro)arylamide en tant que modulateurs du récepteur EP2 |
| EP2149552A1 (fr) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | Dérivés de benzamide 5,6 substitués en tant que modulateurs du récepteur EP2 |
| US20100113512A1 (en) * | 2008-10-30 | 2010-05-06 | Diane Michele Ignar | Method of treatment using novel antagonists or inverse agonists at opioid receptors |
| WO2010080183A1 (fr) * | 2009-01-08 | 2010-07-15 | The Trustees Of Columbia University In The City Of New York | Inhibiteurs non uréiques efficaces de l'époxyde hydrolase soluble |
| WO2011091410A1 (fr) * | 2010-01-25 | 2011-07-28 | Glaxos Smithkline Llc | Antagonistes de trpv4 |
| US20130102600A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| US20130102601A1 (en) * | 2011-10-21 | 2013-04-25 | F. Hoffmann-La Roche Ltd | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| WO2013112751A1 (fr) * | 2012-01-25 | 2013-08-01 | The Trustees Of Columbia University In The City Of New York | Puissants inhibiteurs non-urée de l'époxyde-hydrolase soluble |
| RU2641913C2 (ru) * | 2012-11-16 | 2018-01-23 | Мерк Патент Гмбх | 3-аминоциклопентанкарбоксамидные производные |
| CN104016914B (zh) * | 2014-05-27 | 2016-03-30 | 苏州科技学院 | 一种酰胺化合物的制备方法 |
| US10081616B2 (en) * | 2014-08-28 | 2018-09-25 | X-Chem, Inc. | Soluble epoxide hydrolase inhibitors and uses thereof |
-
2015
- 2015-08-26 US US15/504,223 patent/US10081616B2/en not_active Expired - Fee Related
- 2015-08-26 AU AU2015306643A patent/AU2015306643B2/en not_active Ceased
- 2015-08-26 MA MA040538A patent/MA40538A/fr unknown
- 2015-08-26 CN CN202010138750.0A patent/CN111454246A/zh active Pending
- 2015-08-26 WO PCT/US2015/046878 patent/WO2016033150A1/fr active Application Filing
- 2015-08-26 CN CN201580046202.2A patent/CN107074771B/zh not_active Expired - Fee Related
- 2015-08-26 CA CA2958881A patent/CA2958881A1/fr not_active Abandoned
- 2015-08-26 EP EP15837061.9A patent/EP3186228A4/fr not_active Withdrawn
- 2015-08-26 JP JP2017530962A patent/JP2017525777A/ja active Pending
-
2018
- 2018-08-23 US US16/110,698 patent/US20180362499A1/en not_active Abandoned
-
2020
- 2020-07-22 AU AU2020207828A patent/AU2020207828A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3186228A4 (fr) | 2018-04-18 |
| CN107074771A (zh) | 2017-08-18 |
| US10081616B2 (en) | 2018-09-25 |
| CA2958881A1 (fr) | 2016-03-03 |
| US20170240526A1 (en) | 2017-08-24 |
| EP3186228A1 (fr) | 2017-07-05 |
| CN111454246A (zh) | 2020-07-28 |
| JP2017525777A (ja) | 2017-09-07 |
| CN107074771B (zh) | 2020-03-20 |
| WO2016033150A1 (fr) | 2016-03-03 |
| AU2015306643A1 (en) | 2017-03-16 |
| AU2020207828A1 (en) | 2020-08-13 |
| US20180362499A1 (en) | 2018-12-20 |
| AU2015306643B2 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3129023T3 (da) | Potente opløselige epoxidhydrolase-inhibitorer | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| MA40595A (fr) | Récepteurs chimériques et utilisations de ceux-ci en thérapie immunitaire | |
| MA46700A (fr) | Variants polypeptidiques et ses utilisations | |
| MA53145A (fr) | Agents de liaison cd123 et leurs utilisations | |
| BR112016016293A2 (pt) | Conector e método de uso do mesmo | |
| DK3182962T3 (da) | Compositions and uses of amidine derivatives | |
| MA41997A (fr) | Combinaisons de cannabinoïdes et de n-acyléthanolamines | |
| DK3194564T3 (da) | Trichodermasammensætninger og anvendelsesfremgangsmåder | |
| FR3034778B1 (fr) | Additif dispersant des asphaltenes et ses utilisations | |
| FR3018191B1 (fr) | Utilisations cosmetiques de la swertiamarine | |
| DK2980351T3 (da) | Telemetry system and method of operating the same | |
| EP3177327A4 (fr) | Inhibiteurs de myh7b et utilisations associées | |
| DK3137873T3 (da) | Viscometer and methods of use thereof | |
| MA41022A (fr) | Ciblage lysosomial et utilisations correspondantes | |
| MA40538A (fr) | Inhibiteurs de l'époxyde hydrolase soluble et utilisations de ceux-ci | |
| BR112017012240A2 (pt) | métodos de preparação de composições contendo alcaloides e suas utilizações | |
| DK3132279T3 (da) | Målbestemmelsesfremgangsmåde og -system | |
| FR3039166B1 (fr) | Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes | |
| FR3025698B1 (fr) | Nouvelles utilisations d'esters carboniques de glycerol en agriculture | |
| FR3021660B1 (fr) | Copolymeres de formule (i) et utilisations | |
| MA45473A (fr) | Inhibiteur de c1 estérase conjugué et ses utilisations | |
| ES1116730Y (es) | Conjunto de soporte y proteccion de balizas de trenes. | |
| FR3016128B1 (fr) | Tete de distribution et d'application. | |
| MA46625A (fr) | Inhibiteurs de lsd1 et leurs utilisations médicales |